Veru will announce second quarter fiscal 2024 financial results on May 8, 2024



MIAMI, Fla., May 01, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: NASDAQ: ) is a late-stage clinical-stage biopharmaceutical company focused on developing innovative Drugs for Muscle Preservation for Quality Weight Loss, Oncology and Viral-Induced Acute Respiratory Distress Syndrome, Inc. today announced a conference call and audio network to be held on Wednesday, May 8, 2024 at 8:00 a.m. ET broadcast to discuss its second quarter fiscal 2024 financial results and provide a business update.

The audio webcast can be accessed on the investors page of the Company's website at www.verupharma.com. To join the conference call by phone, dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the company's website for approximately three months. Telephone replays will be available for one week at approximately 12:00 noon ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), pass code 8861692.

About Viru CorporationVeru is a late-stage clinical-stage biopharmaceutical company focused on developing novel medicines to treat metabolic diseases, oncology and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin.

Enobosarm is a selective androgen receptor modulator (SARM) being developed for two indications: (i) a Phase 2b clinical study of enobosarm as an anti-inflammatory drug in older patients with sarcopenic obesity or overweight who are receiving GLP- Treatment to increase fat loss and prevent muscle loss1 RA at risk for muscle atrophy and muscle weakness, and (ii) where adequate funding is available, enobosarm and abemaciclib for the treatment of androgen receptor-positive (AR+), The phase 3 ENABLAR-2 clinical trial is in the second-line treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Sabizabulin is a microtubule-disrupting agent currently in development in a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to further develop sabisabulin for the treatment of virally induced ARDS until we receive funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.

The company also has an FDA-approved commercial product, the FC2 Female Condom® (internal condom), for dual protection against unwanted pregnancy and sexually transmitted infections.

forward-looking statementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding whether and when the planned Phase 2b trial of enobosarm described above will commence or generate key data. or that patients will enter extension studies, the planned design, timing, endpoints, patient populations and patient sizes of such trials, and whether such trials will successfully meet any of their endpoints and whether enobosarm will enhance weight loss or preserve muscle or satisfy obese patients. any unmet needs, whether it will promote weight loss, and whether the company will successfully transition into a late-stage biopharmaceutical company focused on obesity and oncology. Words such as “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “opportunity”, “plan”, “forecast”, “potential”, “estimate”, “should” etc. The words “will,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on the Company's current plans and strategies, reflect the Company's current assessment of the risks and uncertainties associated with its business, and are made as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements contained in this press release as a result of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize, or any assumptions prove incorrect, our actual results may differ from such statements. Results expressed or implied differ materially. Factors that could cause actual results to differ materially from those anticipated by such forward-looking statements include, but are not limited to, the risks detailed in the Company's periodic reports filed with the SEC, including the Company's Form 10-K with respect to such forward-looking statements. For the year ended September 30, 2019, as amended on Form 10-K/A.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Investor and media contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *